Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
ARUP Laboratories, Salt Lake City, Utah, USA.
Int J Lab Hematol. 2023 Jun;45 Suppl 2:79-86. doi: 10.1111/ijlh.14106.
Hereditary hemolytic anemia (HHA) is a heterogeneous group of disorders due to genetically caused defects in red blood cell membrane structure, enzymes, heme and globin synthesis, erythroid proliferation, and differentiation. Traditionally, the diagnostic process is complex and includes a plethora of tests from routine to highly specialized ones. The inclusion of molecular testing has significantly improved the diagnostic yield. The value of molecular testing is broader than just rendering the correct diagnosis, as it may also guide therapeutic decisions. As more molecular modalities become available for clinical use, it is imperative to understand their benefits and disadvantages pertaining to the HHA diagnostics. Re-evaluation of the traditional diagnostic workflow may also bring forth additional benefits. This review focuses on the current state of molecular testing for HHA.
遗传性溶血性贫血(HHA)是一组因红细胞膜结构、酶、血红素和珠蛋白合成、红细胞增殖和分化的遗传缺陷导致的异质性疾病。传统上,诊断过程较为复杂,包括从常规到高度专业化的大量检测。分子检测的加入显著提高了诊断的收益。分子检测的价值不仅在于做出正确的诊断,还可以指导治疗决策。随着更多的分子方法可用于临床应用,了解它们在 HHA 诊断方面的优缺点至关重要。重新评估传统的诊断工作流程也可能带来额外的好处。本综述重点介绍了 HHA 的分子检测现状。